[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594109":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":22,"responsibleParty":38,"collaborators":10,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":42,"sex":47,"minAge":48,"maxAge":10,"enrollmentInfo":49,"targetDuration":10,"studyType":52,"phases":10,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":60,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"identification of clinical and immunological parameters",null,"Identification of clinical and immunological parameters associated with persistence of low-level viremia on effective antiretroviral therapy in people living with HIV with persistent low plasma viral load on ARV treatment, and in people living with HIV with perfect control of viral replication (stable virological suppression).",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Jade GHOSN, professor","CONTACT","0140258000","jade.ghosn@aphp.fr",{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},"Quentin LEHINGRAT, Doctor","0140258080","quentin.lehingrat@aphp.fr",[23],{"facility":24,"status":10,"city":25,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Hôpital Bichat, service des Maladies Infectieuses et Tropicales","Paris","75018","France","FR",{"type":30,"coordinates":31},"Point",[32,33],2.3488,48.85341,{"lat":33,"lon":32},[36,37],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"name":19,"role":15,"phone":20,"phoneExt":10,"email":21},{"type":39,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100594109","role-of-viral-reservoir-immune-activation-and-depletion-in-persistent-viremia-persistent-viremia-in-people-living-with-hiv-on-antiretroviral-therapy-100594109",false,"NCT07015164","Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy","ViPer","PLHIV with persistent low plasma viral load on ARV therapy :\n\n* PLHIV \\> 18 years of age\n* On ARV treatment for at least 3 years\n* Taking one of the following ARV treatments:\n\n  * Tenofovir Alafenamide + Emtricitabine + Bictegravir\n  * Abacavir + Lamivudine + Dolutegravir\n  * Tenofovir Disoproxil Fumarate + Emtricitabine + Dolutegravir\n  * Tenofovir Disoproxil Fumarate + Lamivudine\n\n    \\+ Doravirine\n  * Abacavir + Lamivudine + Doravirine\n* With at least 3 consecutive HIV plasma viral loads between 50 and 1,000 copies\u002FmL over a period of at least 12 months\n* Absence of resistance mutations to current antiretroviral treatments\n\nPLHIV group with perfect control of viral replication (stable virological suppression):\n\n* PLWH \\> 18 years of age\n* On ARV treatment for at least 3 years\n* Taking one of the following ARV treatments:\n\n  * Tenofovir Alafenamide + Emtricitabine + Bictegravir\n  * Abacavir + Lamivudine + Dolutegravir\n  * Tenofovir Disoproxil Fumarate + Emtricitabine + Dolutegravir\n  * Tenofovir Disoproxil Fumarate + Lamivudine\n\n    \\+ Doravirine\n  * Abacavir + Lamivudine + Doravirine\n* With at least 3 plasma HIV viral loads below 50 copies\u002FmL over a period of at least 24 months\n* Absence of resistance mutations to current antiretroviral treatments","ALL","18 Years",{"count":50,"type":51},80,"ESTIMATED","OBSERVATIONAL","Low-level HIV replication in a patient on effective antiretroviral therapy is a relatively frequent event, generating stress for both patient and physician, due to the fear of subsequent virological escape with emergence of resistant virus(es) and\u002For transmission of such virus(es) to partner(s). Understanding the origin of this low-level viral replication would enable informed therapeutic decisions to be made (therapeutic intensification, modification of antiretroviral (ARV) treatment with the use of molecules belonging to other therapeutic classes, or maintenance of the status quo), and reassure patients of the scientific rationale guiding their course of action.\n\nThis is a single-center, cross-sectional study designed to compare the parameters of the cellular viral reservoir between a group of participants with persistent viral replication under ARV treatment and a group of participants with perfect viral replication control (stable virological suppression).\n\nPatients meeting the eligibility criteria will be offered the opportunity to have two additional blood tubes taken for research purposes, as part of an integrated visit to monitor HIV infection, which already includes a venipuncture. Patients meeting these criteria will have been previously identified by a feasibility survey carried out by the clinical research team of the Infectious and Tropical Diseases Department (SMIT) at Hôpital Bichat-Claude Bernard (AP-HP. Nord).",[55],"HIV",[55,57,58,59],"antiretroviral treatment","viral reservoir","persistent viremia","NOT_YET_RECRUITING","2025-06-03",{"date":63,"type":64},"2025-06-11","ACTUAL",{"date":66,"type":51},"2025-06-10",{"date":68,"type":51},"2026-09-11",{"name":5,"class":6},1]